Results 41 to 50 of about 185,596 (291)

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy [PDF]

Cancer Discovery, 2016
Abstract “Liquid biopsy” focusing on the analysis of circulating tumor cells (CTC) and circulating cell-free tumor DNA (ctDNA) in the blood of patients with cancer has received enormous attention because of its obvious clinical implications for personalized medicine. Analyses of CTCs and ctDNA have paved new diagnostic avenues and are,
C. Alix-Panabieres, K. Pantel
openaire   +2 more sources

Detection of Circulating Tumor DNA in Solid Tumors [PDF]

OBM Genetics, 2020
Cancer is characterized by sequential and progressive genetic and epigenetic alterations in key proto-oncogenes and tumor suppressor genes, which ultimately lead to tumor development. Advances in the technology of analysis of molecular mechanisms have increased the efficiency of clinical management of cancer patients.
Ugo Testa, Germana Castelli, Elvira Pelosi   +2 more
openaire   +1 more source

Specific antigen of tumor cell transformed by DNA extracted from SV-40 virus

, 1967
In the immunofluorescent study it has been revealed that rabbit sera immunized with transformed cells induced by SV-40 DNA, produce circulating antibody capable of re:lcting with intranuclear antigens synthesized by SV-40 complyte virus transforming ...
Okada, Shigeru, Grace, James T., Hayashi, Kenj, Kimoto, Tetsuo, Sogabe, Koichi, Shigehisa, Morio   +5 more
core   +1 more source

Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp

Nature Communications
Tebentafusp, a bispecific immune therapy, is the only drug that demonstrated an overall survival benefit in patients with metastatic uveal melanoma (MUM).
Manuel Rodrigues, Toulsie Ramtohul, Aurore Rampanou, José Luis Sandoval, Alexandre Houy, Vincent Servois, Léah Mailly-Giacchetti, Gaelle Pierron, Anne Vincent-Salomon, Nathalie Cassoux, Pascale Mariani, Caroline Dutriaux, Marc Pracht, Thomas Ryckewaert, Jean-Emmanuel Kurtz, Sergio Roman-Roman, Sophie Piperno-Neumann, François-Clément Bidard, Marc-Henri Stern, Shufang Renault   +19 more
doaj   +1 more source

Circulating Tumor Cell and Cell-free Circulating Tumor DNA in Lung Cancer [PDF]

Chonnam Medical Journal, 2016
Circulating tumor cells (CTCs) are tumor cells that are separated from the primary site or metastatic lesion and disseminate in blood circulation. CTCs are considered to be part of the long process of cancer metastasis. As a 'liquid biopsy', CTC molecular examination and investigation of single cancer cells create an important opportunity for providing
Nurwidya, Fariz, Zaini, Jamal, Putra, Andika Chandra, Andarini, Sita, Hudoyo, Achmad, Syahruddin, Elisna, Yunus, Faisal   +6 more
openaire   +2 more sources

circulating tumor DNA in the immediate post-operative setting

Annals of Surgical Oncology, 2023
Abstract Background Circulating tumor DNA (ctDNA) has emerged as an accurate real-time biomarker of disease status across most solid tumor types. Most studies evaluating the utility of ctDNA have focused on time points weeks to months after surgery, which for many cancer types, is significantly later
Vasileios Efthymiou, Natalia Queenan, Markus Haas, Saskia Naegele, Deborah Goss, Daniel L. Faden   +5 more
openaire   +3 more sources

An isoform of 14‐3‐3 protein regulates transbilayer lipid movement at the plasma membrane

FEBS Letters, EarlyView.
Loss of 14‐3‐3ζ in CHO cells confers resistance to exogenous phosphatidylserine (PS) and impairs endocytosis‐independent inward flip‐flop of fluorescent PS at the plasma membrane. RNAi‐mediated knockdown reproduces this defect, while no additive effect is seen in ATP11C‐deficient cells.
Akiko Yamaji‐Hasegawa, Akira Hattori, Masafumi Tsujimoto, Toshihide Kobayashi   +3 more
wiley   +1 more source

The Use of Three-Dimensional DNA Fluorescent In Situ Hybridization (3D DNA FISH) for the Detection of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer (NSCLC) Circulating Tumor Cells. [PDF]

, 2020
Tumor tissue biopsy is often limited for non-small cell lung cancer (NSCLC) patients and alternative sources of tumoral information are desirable to determine molecular alterations such as anaplastic lymphoma kinase (ALK) rearrangements.
Yenkai Lim, Chamindie Punyadeera, Punyadeera, Chamindie, O'Byrne, K, Warkiani, Majid, Punyadeera, C, Majid Warkiani, Lim, Yenkai, Kapeleris, J, Kapeleris, Joanna, Warkiani, M, Kulasinghe, A, Kulasinghe, Arutha, Ken O’Byrne, Joanna Kapeleris, Arutha Kulasinghe, Lim, Y, O'Byrne, Ken   +17 more
core   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Evaluation of exome sequencing to estimate tumor burden in plasma. [PDF]

PLoS ONE, 2014
Accurate estimation of systemic tumor load from the blood of cancer patients has enormous potential. One avenue is to measure the presence of cell-free circulating tumor DNA in plasma.
Daniel Klevebring, Mårten Neiman, Simon Sundling, Louise Eriksson, Eva Darai Ramqvist, Fuat Celebioglu, Kamila Czene, Per Hall, Lars Egevad, Henrik Grönberg, Johan Lindberg   +10 more
doaj   +1 more source